# ClinicalTrials.gov record NCT02967757

> PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02967757-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02967757-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02967757-liraglutide-v1.json
- Content SHA-256: `6d5f7e3110d10d16524fc709aac13ac05c67e54dabd6cc4d2e9a3e7751f17d80`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02967757 ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

## Sources

<a id="source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049"></a>
- **ClinicalTrials.gov record NCT02967757 · retained source version 2023-01-20:9aa28cc0804923e16a352891245c5aed5fdf4a02a78a77211879d3ccb2d08e54** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02967757) (`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02967757." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02967757-liraglutide-v1.json SHA-256: 6d5f7e3110d10d16524fc709aac13ac05c67e54dabd6cc4d2e9a3e7751f17d80.